Comparative safety of two recombinant hepatitis B vaccines in children: data from the Vaccine Adverse Event Reporting System (VAERS) and Vaccine Safety Datalink (VSD)
- PMID: 9635999
- DOI: 10.1016/s0895-4356(98)00014-6
Comparative safety of two recombinant hepatitis B vaccines in children: data from the Vaccine Adverse Event Reporting System (VAERS) and Vaccine Safety Datalink (VSD)
Abstract
Background: Preliminary review of data from the Vaccine Adverse Event Reporting System (VAERS), 1991-1994, revealed that more serious adverse events were reported in children who received a specific brand of recombinant hepatitis B (HepB) vaccine.
Objective: To compare the post-marketing safety experience of the two recombinant HepB vaccines licensed for use in infants and children in the United States.
Design: Review of a case series derived from passive surveillance data in the national VAERS. A retrospective cohort study using data from one health maintenance organization participating in Vaccine Safety Datalink (VSD), a computerized record linkage system. POPULATIONS STUDIED: U.S. children, ages birth-10 years for whom adverse events after HepB vaccine were reported to VAERS, 1991-1994. Children, ages birth-6 years, who received HepB vaccine at Kaiser Permanente Medical Care Program, Northern California, 1991-1994.
Main outcome measures: VAERS reporting rates for each vaccine by manufacturer were calculated from the numbers of reported events occurring within 30 days of HepB vaccination and the number of doses distributed by the manufacturers. VSD event rates for each vaccine were calculated from the numbers of hospitalization or emergency room visits within 30 days of HepB vaccination and the number of vaccine doses administered to the cohort.
Results: In VAERS, higher rates of serious events (i.e., life threatening or resulting in hospitalization or permanent disability) were reported in children who received Vaccine A vs. Vaccine B (relative risk [RR]: 3.13-8.18, P < 0.01), particularly by those vaccinated in the private (RR: 7.62-28.58, P < 0.01), but not public sector (RR: 2.12, P = 0.19). Similar types of events were reported in recipients of both vaccines. In contrast, analysis of VSD data showed no significant difference in rates of hospitalization or ER visits in children who received either HepB vaccine (RR: 0.96-1.25, P > 0.05).
Conclusions: Our investigation reveals that it is unlikely there is a true difference between rates of serious events temporally associated with the two HepB vaccines in children. This study demonstrates the dual roles played by VAERS and VSD in providing a more complete picture of the post-marketing safety profile of childhood vaccines, and underscores the importance of using other analytic studies to evaluate findings from passive surveillance systems of adverse events.
Similar articles
-
Safety of currently licensed hepatitis B surface antigen vaccines in the United States, Vaccine Adverse Event Reporting System (VAERS), 2005-2015.Vaccine. 2018 Jan 25;36(4):559-564. doi: 10.1016/j.vaccine.2017.11.079. Epub 2017 Dec 11. Vaccine. 2018. PMID: 29241647
-
Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.MMWR Surveill Summ. 2003 Jan 24;52(1):1-24. MMWR Surveill Summ. 2003. PMID: 12825543
-
Infant immunization with acellular pertussis vaccines in the United States: assessment of the first two years' data from the Vaccine Adverse Event Reporting System (VAERS).Pediatrics. 2000 Oct;106(4):E51. doi: 10.1542/peds.106.4.e51. Pediatrics. 2000. PMID: 11015546
-
Understanding vaccine safety information from the Vaccine Adverse Event Reporting System.Pediatr Infect Dis J. 2004 Apr;23(4):287-94. doi: 10.1097/00006454-200404000-00002. Pediatr Infect Dis J. 2004. PMID: 15071280 Review.
-
Post-authorization safety surveillance of Ad.26.COV2.S vaccine: Reports to the Vaccine Adverse Event Reporting System and v-safe, February 2021-February 2022.Vaccine. 2023 Jul 5;41(30):4422-4430. doi: 10.1016/j.vaccine.2023.06.023. Epub 2023 Jun 14. Vaccine. 2023. PMID: 37321898 Free PMC article. Review.
Cited by
-
Analysis of deaths following yeast-derived hepatitis B vaccination of infants, China, January 2013 to December 2020.Front Public Health. 2023 Jun 16;11:1170483. doi: 10.3389/fpubh.2023.1170483. eCollection 2023. Front Public Health. 2023. PMID: 37397780 Free PMC article.
-
Exploring the optimal vaccination strategy against hepatitis B virus in childhood (Review).Biomed Rep. 2023 Jun 9;19(1):48. doi: 10.3892/br.2023.1631. eCollection 2023 Jul. Biomed Rep. 2023. PMID: 37383679 Free PMC article. Review.
-
Hepatitis B and A vaccination in HIV-infected adults: A review.Hum Vaccin Immunother. 2015;11(11):2582-98. doi: 10.1080/21645515.2015.1055424. Epub 2015 Jul 24. Hum Vaccin Immunother. 2015. PMID: 26208678 Free PMC article. Review.
-
Terminological challenges in safety surveillance.Drug Saf. 2012 Jan 1;35(1):79-84. doi: 10.2165/11598700-000000000-00000. Drug Saf. 2012. PMID: 22136184 No abstract available.
-
Identifying adverse events of vaccines using a Bayesian method of medically guided information sharing.Drug Saf. 2012 Jan 1;35(1):61-78. doi: 10.2165/11596630-000000000-00000. Drug Saf. 2012. PMID: 22136183
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical